JAZZ
HEALTHCAREJazz Pharmaceuticals PLC
AI Insight
What's Moving JAZZ Today?
No stock-specific AI insight has been generated for JAZZ yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$105.00$243.32
$229.85
Fundamentals
Market Cap$14.5B
P/E Ratio1,918.8
EPS$0.12
Dividend Yield—
Dividend / Share—
ROE0.7%
Profit Margin0.7%
Debt / Equity—
Trading
Volume742K
Avg Volume (10D)—
Shares Outstanding62.8M
JAZZ News
28 articles- Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split AnalystsYahoo Finance·Jun 24, 2026
- Jazz Pharmaceuticals (JAZZ) Expands AbCellera Tie Up As Zepzelca Trial Misses GoalYahoo Finance·Jun 24, 2026
- Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce CollaborationYahoo Finance·Jun 23, 2026
- Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It LooksMotley Fool·Jun 23, 2026
- Will Zepzelca’s Failed LAGOON Trial in Second-Line SCLC Change Jazz Pharmaceuticals' (JAZZ) Narrative?Simply Wall Street·Jun 23, 2026
- JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor TherapiesYahoo Finance·Jun 18, 2026
- Jazz and AbCellera sign deal for T-cell engagers in solid tumoursPharmaceutical-technology·Jun 18, 2026
- Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Fed Rates AnnouncementYahoo Finance·Jun 17, 2026
- Jazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid TumorsAdvfn·Jun 17, 2026
- Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific AntibodiesYahoo Finance·Jun 17, 2026
- Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic HypersomniaYahoo Finance·Jun 16, 2026
- Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?Yahoo Finance·Jun 15, 2026
- Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)Yahoo Finance·Jun 15, 2026
- Sector Update: Healthcare Stocks Softer Late AfternoonYahoo Finance·Jun 12, 2026
- Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung CancerYahoo Finance·Jun 12, 2026
- New Xywav Data And FDA Ruling Put Jazz Valuation In FocusYahoo Finance·Jun 11, 2026
- Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says AnalystBenzinga·Jun 10, 2026
- 3 Unpopular Stocks We Find RiskyYahoo Finance·Jun 8, 2026
- Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Xywav And Ziihera Updates And Strong Quarterly ResultsSimply Wall Street·Jun 7, 2026
- Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?Yahoo Finance·Jun 4, 2026
- Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic HypersomniaYahoo Finance·Jun 4, 2026
- Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15%Yahoo Finance·May 31, 2026
- What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One YearMotley Fool·May 30, 2026
- Jazz director sells shares after option exercise | JAZZ Insider TradingStock Titan·May 27, 2026
- Jazz Pharmaceuticals (JAZZ) director sells 2,000 Ordinary Shares in open-market tradeStock Titan·May 27, 2026
- Jazz Pharmaceuticals plc SEC FilingStock Titan·May 22, 2026
- Jazz Pharmaceuticals (JAZZ) Is Up 8.5% After Q1 Profit Rebound And Ziihera Priority Review – Has The Bull Case Changed?Simply Wall Street·May 11, 2026
- Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsightGlobeNewswire Inc.·Apr 20, 2026
All 28 articles loaded
Price Data
Open$229.76
Previous Close$230.25
Day High$234.08
Day Low$228.30
52 Week High$243.32
52 Week Low$105.00
52-Week Range
$105.00$243.32
$229.85
Fundamentals
Market Cap$14.5B
P/E Ratio1,918.8
EPS$0.12
Dividend Yield—
Dividend / Share—
ROE0.7%
Profit Margin0.7%
Debt / Equity—
Trading
Volume742K
Avg Volume (10D)—
Shares Outstanding62.8M
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—